Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Down 5.4% - Here's What Happened

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report)'s stock price was down 5.4% on Tuesday . The company traded as low as $18.42 and last traded at $18.54. Approximately 25,334 shares were traded during trading, a decline of 96% from the average daily volume of 581,491 shares. The stock had previously closed at $19.60.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on KNSA shares. JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Evercore ISI increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Finally, Wedbush reissued an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Trading Up 0.5 %

The stock has a market cap of $1.43 billion, a PE ratio of -140.99 and a beta of 0.32. The company's 50 day moving average is $19.86 and its 200-day moving average is $22.94.

Insider Buying and Selling

In other news, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $18.24, for a total value of $255,360.00. Following the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at approximately $1,622,904. This trade represents a 13.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the firm's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,092 shares of company stock valued at $745,589 in the last quarter. Company insiders own 54.57% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Oberweis Asset Management Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 18.0% in the 4th quarter. Oberweis Asset Management Inc. now owns 237,200 shares of the company's stock worth $4,692,000 after buying an additional 36,200 shares during the last quarter. Voya Investment Management LLC lifted its position in shares of Kiniksa Pharmaceuticals by 16.8% in the 4th quarter. Voya Investment Management LLC now owns 19,988 shares of the company's stock worth $395,000 after buying an additional 2,870 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Kiniksa Pharmaceuticals by 23.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,111 shares of the company's stock worth $299,000 after buying an additional 2,881 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after buying an additional 4,575 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in Kiniksa Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after purchasing an additional 1,374 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.